US EditionUS aid cuts halt HIV vaccine research in South Africa, with global impact
SOUTH AFRICA, JUL 13 – US aid cuts eliminate $46 million in funding for HIV research, causing layoffs and delaying trials amid South Africa's high HIV infection rates, officials said.
- Earlier this month, the U.S. under President Donald Trump halted the BRILLIANT HIV vaccine project with a $46 million funding cut, just a week before trials were to begin.
- Amid U.S. under President Donald Trump’s broader foreign aid reduction, all funding for South Africa's HIV vaccine project was withdrawn, partly due to baseless claims targeting the white Afrikaner minority.
- Just a week before trials, vaccines showed immune responses, indicating readiness despite funding cuts, as noted by researchers including Glenda Gray.
- As a result of US aid cuts, about 8,000 South African health workers have been laid off, with infections expected to increase, according to sources.
- South African universities and science councils could lose about $107 million over five years, threatening the country's HIV and tuberculosis research capacity, with broader global implications.
27 Articles
27 Articles
U.S. aid cuts halt HIV vaccine research in South Africa, with global impact
Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were high for another step toward limiting one of history’s deadliest pandemics. Then the email arrived.
US Aid Cuts Halt HIV Vaccine Research In South Africa, With Global Impact
Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were high for another step toward limiting one of history's deadliest pandemics. Then the email arrived.
Funding Cuts Stall Crucial HIV Research in South Africa
The withdrawal of U.S. funding under the Trump administration has halted key HIV vaccine trials in South Africa, part of a broader cutback on foreign aid. The BRILLIANT project, integral to HIV medication development, struggles to survive, with significant consequences for global health research and employment in Africa.
Miguel, a 63-year-old Los Angeles teacher, recently celebrated the thirty-eighth anniversary of his HIV diagnosis. The doctor had told him that he would die in a couple of years.Miguel started taking AZT (azidotimidine), the first antiretroviral drug to treat HIV and AIDS. Then he went on to a succession of other medications. While taking one called Crixivan (indinavir), his cheeks were sunk and his chin fat increased, features of the first anti…
Coverage Details
Bias Distribution
- 67% of the sources lean Left
To view factuality data please Upgrade to Premium
